



149/A and B (modified PTO/SB/08)

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/735,592

ATTY. DOCKET NO.: C1037.70038US01

FILING DATE: December 11, 2003

CONFIRMATION NO.: 2533

APPLICANT: Krieg et al.

GROUP ART UNIT: 1645

EXAMINER: Nita M. Minnifield

Sheet 1 of 2

## U.S. PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A350	7,250,403	B2	Van Nest et al.	07-31-2007
	A351	7,255,868	B2	Fearon et al.	08-14-2007
	A352	7,262,286	B2	Kandimalla et al.	08-28-2007
	A353	7,354,711	B2	Macfarlane	04-08-2008
	A354	2002-0168340	A1	Agrawal	11-14-2002
	A355	2003-0129605	A1	Yu et al.	07-10-2003
	A356	2003-0212029	A1	Agrawal et al.	11-13-2003
	A357	2006-0019918	A1	Agrawal et al.	01-26-2006
	A358	2007-0190073	A1	Tuck et al.	08-16-2007
	A359	2007-0280929	A1	Hoerr et al.	12-06-2007
	A360	2008-0026011	A1	Krieg et al.	01-31-2008
	A361	2008-0031936	A1	Krieg et al.	02-07-2008
	A362	2008-0045473	A1	Uhlmann et al.	02-21-2008

## FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>#</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B98	WO	03/000232	A2	Yissum Research Development Company of the Hebrew University of Jerusalem	01-03-2003	
	B99	WO	2004/004743	A1	Curevac GmbH	01-15-2004	
	B100	WO	2004/012669	A2	The Government of the United States	02-12-2004	
	B101	WO	2005/004907	A1	Cytos Biotechnology AG	01-20-2005	
	B102	WO	2005/009355	A2	Hybridon, Inc.	02-03-2005	
	B103	WO	2005/059517	A2	University of Massachusetts	06-30-2005	
	B104	WO	2005/072290	A2	Joslin Diabetes Center	08-11-2005	
	B105	WO	2005/079419	A2	The Regents of the University of California	09-01-2005	
	B106	WO	2008/030455	A2	Coley Pharmaceutical Group, Inc.	03-13-2008	
	B107	WO	2008/033432	A2	Coley Pharmaceutical Group, Inc.	03-20-2008	
	B108	WO	2008/039538	A2	Coley Pharmaceutical Group, Inc.	04-03-2008	

EXAMINER:

/N. M. Minnifield/ (03/09/2009)

DATE CONSIDERED:

<sup>#</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/735,592	ATTY. DOCKET NO.: C1037.70038US01
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				FILING DATE: December 11, 2003	CONFIRMATION NO.: 2533
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nita M. Minnifield
Sheet	2	of	2		

**OTHER ART — NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials <sup>1</sup>	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C340	ALEXAKIS et al., Microencapsulation of DNA within alginate microspheres and crosslinked chitosan membranes for in vivo application. Appl Biochem Biotechnol. 1995 Jan;50(1):93-106.	
	C341	HARTMANN et al., Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41.	
	C342	KANDIMALLA et al., Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochem Biophys Res Commun. 2003 Jul 11;306(4):948-53.	
	C343	KRIEG, Now I know my CpGs. Trends Microbiol. 2001 Jun;9(6):249-52.	
	C344	LEE et al., Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol. 2000 Oct 1;165(7):3631-9.	
	C345	MUTWIRI et al., Biological activity of immunostimulatory CpG DNA motifs in domestic animals. Vet Immunol Immunopathol. 2003 Jan 30;91(2):89-103.	
	C346	STOREY et al., Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res. 1991 Aug 11;19(15):4109-14.	
	C347	YAMADA et al., Effect of suppressive DNA on CpG-induced immune activation. J Immunol. 2002 Nov 15;169(10):5590-4.	
	C348	YU et al., Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochem Biophys Res Commun. 2002 Sep 13;297(1):83-90.	
	C349	ZHANG et al., Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant. Antimicrob Agents Chemother. 1999 Feb;43(2):347-53.	

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_, filed \_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:  /N. M. Minnifield/ (03/09/2009)	DATE CONSIDERED:
--	------------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.